Bentham Science Logo

Current Drug Targets

Volume 21, 16 Issues, 2020
ISSN: 1873-5592 (Online)
ISSN: 1389-4501 (Print)
This journal supports open access

Ranking and Category

  • 131st of 267 in

    Pharmacology & Pharmacy

Order Your Article Before Print

Meet the Executive Guest Editor(s)

L. Scotti
Federal University of Paraíba
João Pessoa, PB
Brazil
PhD in Cosmetology and Molecular Modeling at University of São Paulo. She made 3 years of Post-Doctorate in Pharmaceuticals at the Laboratory of Planning and Synthesis of Potentially Active Chemotherapies in Tropical Endemics, Faculty of Pharmaceutical Sciences, USP. From 2010 to 2012 post-doctorate in Federal University of Paraíba and from 07/2012 to 07/2013 post-doctorate at the Federal University of Pernambuco. She has experience in Pharmacology Biochemistry and Molecular, acting mainly in the following areas: natural products, Molecular Modeling, QSAR and Chemometrics. Professor of the Post-Graduate Program of Bioactive Natural and Synthetic Products of the Federal University of Paraíba.


M. Shammas
Harvard (Dana Farber) Cancer Institute
Boston, MA
USA
Dr. Shammas is employed as a Lead Scientist in the field of Translational Cancer Research at Harvard (Dana Farber) Cancer Institute, Boston, USA. His research focuses on understanding mechanisms underlying genomic instability and their translational significance in cancer, including Barrett’s esophageal adenocarcinoma. He has developed novel tools/assay systems to study genomic evolution in cancer and has identified key targets and novel drugs to inhibit/reduce genomic evolution, whether intrinsic to cancer cell or that induced/increased by chemotherapeutic agents. These drugs have potential to inhibit tumor growth, overcome/minimize harmful genomic impact of chemotherapy and inhibit/delay progression of cancer to advanced and more aggressive stages. He is a co-author over 60 scientific publications including book chapters and has trained a number of students (undergraduate, graduate), postdoctoral fellows and clinical fellows. He has served and/or serving as Principal Investigator, Co-Principal Investigator and/or Co-investigator on several research grants from the NIH (USA), including R01 grant or even larger grants, including Program Project and Specialized Programs of Research Excellence grants from NIH. He is serving or has served as a Founding Editor, Editor, Lead Guest Editor and/or Guest Associate Editor for several scientific journals, a Grant Reviewer, and as an External Examiner for PhD students for Universities abroad.



Editor-in-Chief

Francis J. Castellino
(14643 citations)
Kleiderer-Pezold Professor of Biochemistry
Director, W.M. Keck Center for Transgene Research
Dean Emeritus, College of Science
230 Raclin-Carmichael Hall, University of Notre Dame
Notre Dame, IN 46556
USA

View Full Editorial Board

Journal History

Current Drug Targets Journal was launched in 2000. Dr. Francis J. Castellino serves as the Editor-in-Chief of the journal.
Track Your Manuscript:


Scopus CiteScore Metrics: 2.56

Advertisement

Thyroid Awareness Month

Related Journals

Related eBooks

eBooks Catalog